Skip to main content

Cardiotoxicity of novel anti-cancer therapies

The cardiotoxicity of cancer treatments is a significant research space in the cardio-oncology field. 

For this Cardio-Oncology article collection, we welcome submissions examining cardiotoxicity caused by chemotherapy, radiotherapy, molecular-targeted agents, and immune-modulating agents. Manuscripts investigating cardiotoxicity related to novel cancer treatments will be highly appreciated.

Submissions can be made through the journal's editorial management system
 

New Content Item

 

  1. Immune checkpoint inhibitors (ICI) are associated with immune-mediated adverse effects, potentially involving any organ. ICI has also been associated with an increased risk of cardiovascular disease in cancer ...

    Authors: Charlie Wang, Sophia Zoungas, Mabel Yan, Rory Wolfe, Andrew Haydon, Mark Shackleton, Mark Voskoboynik, Maggie Moore, Miles C. Andrews, Stephen J. Nicholls and Victoria Mar
    Citation: Cardio-Oncology 2022 8:23
  2. The full range of cardiovascular complications related to the use of Immune checkpoint inhibitors (ICI) is not fully understood. We aim to describe the spectrum of cardiovascular adverse events (cvAEs) by pres...

    Authors: Maria Sol Andres, Sivatharshini Ramalingam, Stuart D. Rosen, John Baksi, Rajdeep Khattar, Yulia Kirichenko, Kate Young, Nadia Yousaf, Alicia Okines, Robert Huddart, Kevin Harrington, Andrew J.S. Furness, Samra Turajlic, Lisa Pickering, Sanjay Popat, James Larkin…
    Citation: Cardio-Oncology 2022 8:21
  3. We report the case of a 59-year-old female patient with no previous cardiovascular disease treated for Breast cancer with Capecitabine. Shortly after starting treatment, she developed recurrent angina. An exer...

    Authors: George B. Strobel, Shiva P. Ponamgi, Attila Roka and Ahmed S. A. Aboeata
    Citation: Cardio-Oncology 2022 8:19
  4. Acute pericarditis is caused by the inflammation of the pericardium which can result in an effusion around the heart. Proton beam therapy causing radiation-induced pericarditis is not a well-known cause of per...

    Authors: Rahul Gupta, Muling Lin, Gary M. Freedman, Deborah W. Sundlof and Cheri Silverstein Fadlon
    Citation: Cardio-Oncology 2022 8:9
  5. Androgen deprivation therapy (ADT) and radiotherapy (RT) are the mainstay treatment for localized prostate cancer and recurrence after surgery. Cardiovascular (CV) toxicity of ADT is increasingly recognized, a...

    Authors: Youquan Li, Whee Sze Ong, Ma Than Than Shwe, Nelson Ling Fung Yit, Sheriff Zhan Hong Quek, Eric Pei Ping Pang, Wen Shen Looi, Wen Long Nei, Michael Lian Chek Wang, Melvin Lee Kiang Chua, Terence Wee Kiat Tan, Eu Tiong Chua, Choon Ta Ng and Jeffrey Kit Loong Tuan
    Citation: Cardio-Oncology 2022 8:4
  6. Checkpoint-inhibitor immunotherapies have had a profound effect in the treatment of cancer by inhibiting down-regulation of T-cell response to malignancy. The cardiotoxic potential of these agents was first de...

    Authors: Zachary L. Brumberger, Mary E. Branch, Max W Klein, Austin Seals, Michael D. Shapiro and Sujethra Vasu
    Citation: Cardio-Oncology 2022 8:3
  7. Ibrutinib is a Bruton’s tyrosine kinase inhibitor used in the treatment of hematological malignancies. The most common cardiotoxicity associated with ibrutinib is atrial arrhythmia (atrial fibrillation and flu...

    Authors: Juan Carlo Avalon, Jacob Fuqua, Tyler Miller, Seth Deskins, Chelby Wakefield, Austin King, Sonya Inderbitzin-Brooks, Christopher Bianco, Lauren Veltri, Wei Fang, Michael Craig, Abraham Kanate, Kelly Ross, Midhun Malla and Brijesh Patel
    Citation: Cardio-Oncology 2021 7:38
  8. Gilteritinib is a novel FMS-like tyrosine kinase 3 inhibitor recently approved by the United States Food and Drug Administration in 2018 for relapsed or refractory acute myeloid leukemia. However, gilteritinib...

    Authors: Lisa Kim, Brian Fowler, Courtney M. Campbell, Jeremy Slivnick, Haseeb Nawaz, Yaquta Kaka, Patrick Ruz, Ajay Vallakati, Ragavendra Baliga, Sumithira Vasu and Daniel Addison
    Citation: Cardio-Oncology 2021 7:36
  9. Recent advances in the treatment algorithms of early breast cancer have markedly improved overall survival. However, anthracycline- and trastuzumab-associated cardiotoxicity may lead to dose-reduction or halt ...

    Authors: A Mecinaj, G Gulati, SL Heck, E Holte, MW Fagerland, AI Larsen, E.S Blix, J Geisler, T Wethal and T Omland
    Citation: Cardio-Oncology 2021 7:33
  10. Modern therapies in oncology have increased cancer survivorship, as well as the incidence of cardiovascular adverse events. While immune checkpoint inhibitors have shown significant clinical impact in several ...

    Authors: Jessica Castrillon Lal, Sherry-Ann Brown, Patrick Collier and Feixiong Cheng
    Citation: Cardio-Oncology 2021 7:19
  11. The CBR3 V244M single nucleotide polymorphism has been linked to the risk of anthracycline-related cardiomyopathy in survivors of childhood cancer. There have been limited prospective studies examining the impact...

    Authors: Jennifer K. Lang, Badri Karthikeyan, Adolfo Quiñones-Lombraña, Rachael Hageman Blair, Amy P. Early, Ellis G. Levine, Umesh C. Sharma, Javier G. Blanco and Tracey O’Connor
    Citation: Cardio-Oncology 2021 7:17
  12. Breast cancer is the most common female cancer worldwide. Effective therapies including doxorubicin and trastuzumab have improved survival, but are associated with a substantial risk of cardiovascular disease....

    Authors: Rebecca K. Hoffman, Bang-Jin Kim, Payal D. Shah, Joseph Carver, Bonnie Ky and Sandra Ryeom
    Citation: Cardio-Oncology 2021 7:15
  13. Trastuzumab reduces risk of breast cancer recurrence but carries risk of cardiotoxicity that may be reversible upon treatment cessation and institution of left ventricular (LV) enhancement therapies (LVETx). W...

    Authors: Ren Jie Robert Yao, Jordan Gibson, Christine Simmons and Margot K. Davis
    Citation: Cardio-Oncology 2021 7:12
  14. Immune checkpoint inhibitors (ICIs) are a novel class of anticancer agents that have demonstrated clinical response for both solid and hematological malignancies. ICIs are associated with development of immune...

    Authors: Nida Waheed, Michael G. Fradley, David L. DeRemer, Ahmad Mahmoud, Chintan P. Shah, Taimour Y. Langaee, Gloria P. Lipori, Keith March, Carl J. Pepine, Rhonda M. Cooper-DeHoff, Yonghui Wu and Yan Gong
    Citation: Cardio-Oncology 2021 7:10
  15. Cancer therapy-related cardiac dysfunction (CTRD) is a major source of morbidity and mortality in long-term cancer survivors. Decreased GLS predicts decreased left ventricular ejection fraction (LVEF) in patie...

    Authors: Raquel Araujo-Gutierrez, Kalyan R. Chitturi, Jiaqiong Xu, Yuanchen Wang, Elizabeth Kinder, Alpana Senapati, L. Bindu Chebrolu, Mahwash Kassi and Barry H. Trachtenberg
    Citation: Cardio-Oncology 2021 7:4
  16. Trastuzumab-induced cardiotoxicity (TIC) can lead to early discontinuation of adjuvant therapy, however there is limited evidence on long-term survival outcomes in patients with operable human epidermal growth...

    Authors: Sagar Sardesai, Jasmine Sukumar, Mahmoud Kassem, Marilly Palettas, Julie Stephens, Evan Morgan, Daniel Addison, Ragavendra Baliga, Daniel G. Stover, Jeffrey VanDeusen, Nicole Williams, Mathew Cherian, Maryam Lustberg, Robert Wesolowski and Bhuvaneswari Ramaswamy
    Citation: Cardio-Oncology 2020 6:26
  17. Cancer therapy-related cardiac dysfunction (CTRCD) is a critical problem with an impact on both oncological and cardiovascular prognosis, especially when it prevents patients from receiving cancer treatment. S...

    Authors: Vanesa Gregorietti, Teresa Lopez Fernandez, Diego Costa, Elías Ortega Chahla and Andrés J. Daniele
    Citation: Cardio-Oncology 2020 6:24

    The Short communication to this article has been published in Cardio-Oncology 2020 6:25

  18. Proteasome inhibitors such as carfilzomib are indicated in multiple myeloma patients showing relapse and/or refractoriness of clonal activity. However, this therapy has been associated with a significant incid...

    Authors: Arnold Méndez-Toro, Cándida Díaz-Brochero and Estivalis Acosta-Gutiérrez
    Citation: Cardio-Oncology 2020 6:17
  19. Doxorubicin remains one of the most common causes of cardiotoxicity in patients with lymphoma, leading to significant morbidity and mortality. Early decline in left ventricular (LV) ejection fraction predicts ...

    Authors: Maria Isabel Camara Planek, Ahmad Manshad, Kyaw Hein, Mohamad Hemu, Fatima Ballout, Rajiv Varandani, Parameswaran Venugopal and Tochukwu Okwuosa
    Citation: Cardio-Oncology 2020 6:10
  20. Anthracyclines are a mainstay of chemotherapy. However, a relatively frequent adverse outcome of anthracycline treatment is cardiomyopathy. Multiple genetic studies have begun to dissect the complex genetics u...

    Authors: Timothy N. McOwan, Lauren A. Craig, Anne Tripdayonis, Kathy Karavendzas, Michael M. Cheung, Enzo R. Porrello, Rachel Conyers and David A. Elliott
    Citation: Cardio-Oncology 2020 6:5
  21. Irradiation of the heart during cancer radiotherapy is associated with a dose-dependent risk of heart failure. Animal studies have demonstrated that irradiation leads to an inflammatory response within the hea...

    Authors: Justin M. Canada, Georgia K. Thomas, Cory R. Trankle, Salvatore Carbone, Hayley Billingsley, Benjamin W. Van Tassell, Ronald K. Evans, Ryan Garten, Elisabeth Weiss and Antonio Abbate
    Citation: Cardio-Oncology 2020 6:2
  22. Continuous infusion of doxorubicin or dexrazoxane pre-treatment prior to bolus doxorubicin are proven strategies to protect against doxorubicin-induced cardiotoxicity. Recently, global longitudinal peak systol...

    Authors: Jieli Li, Hui-Ming Chang, Jose Banchs, Dejka M. Araujo, Saamir A. Hassan, Elizabeth A. Wagar, Edward T. H. Yeh and Qing H. Meng
    Citation: Cardio-Oncology 2020 6:1
  23. Cancer diagnostics and therapies have improved steadily over the last few decades, markedly increasing life expectancy for patients at all ages. However, conventional and newer anti-neoplastic therapies can ca...

    Authors: Neha Bansal, M. Jacob Adams, Sarju Ganatra, Steven D. Colan, Sanjeev Aggarwal, Rudolf Steiner, Shahnawaz Amdani, Emma R. Lipshultz and Steven E. Lipshultz
    Citation: Cardio-Oncology 2019 5:18
  24. Dexrazoxane protects from lower-cumulative-dose doxorubicin cardiotoxicity, but the effect of dexrazoxane in children with sarcoma treated with higher-cumulative-dose doxorubicin is unknown.

    Authors: Lisa M. Kopp, Richard B. Womer, Cindy L. Schwartz, David H. Ebb, Vivian I. Franco, David Hall, Donald A. Barkauskas, Mark D. Krailo, Holcombe E. Grier, Paul A. Meyers, Leonard H. Wexler, Neyssa M. Marina, Katherine A. Janeway, Richard Gorlick, Mark L. Bernstein and Steven E. Lipshultz
    Citation: Cardio-Oncology 2019 5:15
  25. 5-Fluorouracil (5-FU) is an antimetabolite chemotherapy used for a variety of solid tumors. It has the potential to cause a wide spectrum of cardiotoxicity, ranging from asymptomatic electrocardiographic chang...

    Authors: Cai Yuan, Hiral Parekh, Carmen Allegra, Thomas J. George and Jason S. Starr
    Citation: Cardio-Oncology 2019 5:13
  26. Cardiotoxicity is a potential complication of anticancer therapy. While guidelines have been developed to assist practitioners, an effective, evidence based clinical pathway for the treatment of cardiotoxicity...

    Authors: Robyn A. Clark, Tania S. Marin, Alexandra L. McCarthy, Julie Bradley, Suchi Grover, Robyn Peters, Christos S. Karapetis, John J. Atherton and Bogda Koczwara
    Citation: Cardio-Oncology 2019 5:14
  27. Cardiovascular disease (CVD) is the leading non-malignant cause of death in childhood cancer survivors. Heightened risk of CVD is often attributable to treatment with anthracycline chemotherapy. Anthracycline-...

    Authors: Treya M. Long, Channa E. Marsh, Lawrence G. Dembo, Philip Watson, Karen E. Wallman, Thomas S. Walwyn, Catherine S. Choong and Louise H. Naylor
    Citation: Cardio-Oncology 2019 5:11
  28. Cardiotoxicity is an adverse effect of trastuzumab (TRA) in the treatment of human epidermal growth factor 2 positive (HER2+) breast cancer. Current literature on the cardioprotective effects of agents targete...

    Authors: Melissa Y. Y. Moey, Darla K. Liles and Blase A. Carabello
    Citation: Cardio-Oncology 2019 5:9
  29. Early identification of cardiac dysfunction by non-invasive imaging in HER2-positive breast cancer patients treated with trastuzumab is challenging. In particular multigated acquisition (MUGA) scan, which is m...

    Authors: Nathalie I. Bouwer, Crista Liesting, Marcel J. M. Kofflard, Sylvia M. Sprangers-van Campen, Jasper J. Brugts, Jos J. E. M. Kitzen, Michael A. Fouraux, Mark-David Levin and Eric Boersma
    Citation: Cardio-Oncology 2019 5:4
  30. Anthracycline chemotherapy is an effective and widely used treatment for solid tumors and hematological malignancies regardless of its known cardiotoxicity. The mechanisms of the cardiotoxicity are not fully u...

    Authors: Amanda J. Favreau-Lessard, Hagen Blaszyk, Michael A. Jones, Douglas B. Sawyer and Ilka M. Pinz
    Citation: Cardio-Oncology 2019 5:2
  31. Cardiotoxicity associated with anthracycline-based chemotherapies has limited their use in patients with preexisting cardiomyopathy or heart failure. Dexrazoxane protects against the cardiotoxic effects of ant...

    Authors: Sarju Ganatra, Anju Nohria, Sachin Shah, John D. Groarke, Ajay Sharma, David Venesy, Richard Patten, Krishna Gunturu, Corrine Zarwan, Tomas G. Neilan, Ana Barac, Salim S. Hayek, Sourbha Dani, Shantanu Solanki, Syed Saad Mahmood and Steven E. Lipshultz
    Citation: Cardio-Oncology 2019 5:1
  32. Doxorubicin chemotherapy is used across a range of adult and pediatric malignancies. Cardiac toxicity is common, and dysfunction develops over time in many patients. Biomarkers used for predicting late cardiac...

    Authors: Andrew Poklepovic, Yuesheng Qu, Molly Dickinson, Michael C. Kontos, Maciej Kmieciak, Elizabeth Schultz, Dipankar Bandopadhyay, Xiaoyan Deng and Rakesh C. Kukreja
    Citation: Cardio-Oncology 2018 4:7
  33. Anthracycline induced cardiomyopathy is a major cause of mortality and morbidity among pediatric cancer survivors. It has been postulated that oxidative stress induction and inflammation may play a role in the...

    Authors: Olga H. Toro-Salazar, Ji Hyun Lee, Kia N. Zellars, Paige E. Perreault, Kathryn C. Mason, Zhu Wang, Kan N. Hor, Eileen Gillan, Caroline J. Zeiss, Daniel M. Gatti, Brooke T. Davey, Shelby Kutty, Bruce T. Liang and Francis G. Spinale
    Citation: Cardio-Oncology 2018 4:4
  34. Carfilzomib, an epoxyketone proteasome inhibitor, has demonstrated improved progression-free survival in patients when used with standard treatment (lenalidomide and dexamethasone) in patients with relapsed mu...

    Authors: Eric H. Yang, Cynthia Courtney, Vinisha Garg, Michael G. Fradley and Gary J. Schiller
    Citation: Cardio-Oncology 2018 4:2
  35. Cardiotoxicity from anticancer therapy affects heart function and structure. Cardiotoxicity can also lead to accelerated development of chronic diseases, especially in the presence of risk factors.

    Authors: Robyn A. Clark, Tania S. Marin, Narelle M. Berry, John J. Atherton, Jonathon W. Foote and Bogda Koczwara
    Citation: Cardio-Oncology 2017 3:6
  36. Antineoplastic therapy with the tyrosine kinase inhibitor pazopanib in patients with advanced/metastatic renal cell carcinoma (mRCC) has been associated with hypertension (HTN), cardiomyopathy, and cardiac dys...

    Authors: Daniel Pinkhas, Thai Ho and Sakima Smith
    Citation: Cardio-Oncology 2017 3:5
  37. Proteasome inhibitors (PI) bortezomib and carfilzomib are cornerstone therapies for multiple myeloma. Higher incidence of cardiac adverse events (CAEs) has been reported in patients receiving carfilzomib. Howe...

    Authors: John H. Chen, Daniel J. Lenihan, Sharon E. Phillips, Shelton L. Harrell and Robert F. Cornell
    Citation: Cardio-Oncology 2017 3:4
  38. Doxorubicin (DOX) is a very effective anticancer medication that is commonly used to treat hematological malignancies and solid tumors. Nevertheless, DOX is known to have cardiotoxic effects that may lead to c...

    Authors: Beshay N. Zordoky, M. Judith Radin, Lois Heller, Anthony Tobias, Ilze Matise, Fred S. Apple, Sylvia A. McCune and Leslie C. Sharkey
    Citation: Cardio-Oncology 2016 2:4
  39. The cardiotoxicity of doxorubicin is becoming an interdisciplinary point of interest given a growing population of cancer survivors. The complex and not completely understood pathogenesis of this complication ...

    Authors: Antonella De Angelis, Konrad Urbanek, Donato Cappetta, Elena Piegari, Loreta Pia Ciuffreda, Alessia Rivellino, Rosa Russo, Grazia Esposito, Francesco Rossi and Liberato Berrino
    Citation: Cardio-Oncology 2016 2:2
  40. New anti-cancer drugs that inhibit the vascular endothelial growth factor (VEGF) signaling pathway are highly effective in the treatment of solid tumors, however concerns remain regarding their cardiovascular ...

    Authors: Yishay Wasserstrum, Ran Kornowski, Pia Raanani, Avi Leader, Oren Pasvolsky and Zaza Iakobishvili
    Citation: Cardio-Oncology 2015 1:6
  41. Subacute cardiotoxicity, consisting of acute myocyte damage and associated left ventricular dysfunction, occurs early during anthracycline therapy. We investigated the impact of myocardial dysfunction, defined...

    Authors: Olga H. Toro-Salazar, Eileen Gillan, Joanna Ferranti, Andrea Orsey, Karen Rubin, Shailendra Upadhyay, Wojciech Mazur and Kan N. Hor
    Citation: Cardio-Oncology 2015 1:1